Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

April 30, 2014

Conditions
Non-ST Elevation Myocardial Infarction
Interventions
DRUG

Tocilizumab 280 mg

Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl

DRUG

NaCl 0.9% 100 ml

Placebo

Trial Locations (2)

7006

St Olavs Hospital, Trondheim

0424

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

South-Eastern Norway Regional Health Authority

OTHER

collaborator

University of Oslo

OTHER

collaborator

Norwegian University of Science and Technology

OTHER

lead

Oslo University Hospital

OTHER

NCT01491074 - Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction | Biotech Hunter | Biotech Hunter